Table 1.
NBN variant | Unselected prostate cancer cases |
Familial prostate cancer cases |
Control No./Total (%) | ||||
---|---|---|---|---|---|---|---|
No./Total (%) | OR (95% CI) | p-value | No./Total (%) | OR (95% CI) | p-value | ||
657del5 | 74/5,189 (1.4) | 2.5 (1.7-3.8) | < 0.001 | 15/635 (2.4) | 4.2 (2.3-7.8) | < 0.001 | 35/6,152 (0.6) |
R215W | 13/5,189 (0.25) | 1.3 (0.5-3.4) | 0.762 | 2/635 (0.3) | 1.6 (0.3-8.2) | 0.889 | 6/3,122a) (0.2) |
I171V | 140/5,189 (2.7) | 1.2 (0.9-1.5) | 0.351 | 8/635 (1.3) | 0.5 (0.3-1.1) | 0.120 | 73/3,122a) (2.3) |
E185Q (GG genotype) | 2,207/5,189 (42.6) | 1.0 (0.9-1.1) | 0.994 | 270/634 (42.6) | 1.0 (0.8-1.2) | 0.982 | 2,617/6,152 (42.5) |
E185Q (GC genotype) | 2,389/5,189 (46.0) | 1.0 (0.9-1.1) | 0.565 | 287/634 (45.3) | 1.0 (0.8-1.2) | 0.952 | 2,798/6,152 (45.5) |
E185Q (CC genotype) | 593/5,189 (11.4) | 0.9 (0.8-1.1) | 0.379 | 77/518 (12.1) | 1.0 (0.8-1.3) | 0.954 | 737/6,152 (12.0) |
OR, odds ratio; CI, confidence interval.
For R215W and R215W variants 3,122 controls were only genotyped.